Leukemia Research
Volume 30, Issue 4 , Pages 437-447 , April 2006

Expression of PDZ-binding kinase (PBK) is regulated by cell cycle-specific transcription factors E2F and CREB/ATF

Received 3 June 2005 ,Revised 9 August 2005 ,Accepted 11 August 2005.

References 

  1. Gaudet S, Branton D, Lue RA. Characterization of PDZ-binding kinase, a mitotic kinase. Proc Natl Acad Sci USA. 2000;97:5167–5172
  2. Abe Y, Matsumoto S, Kito K, Ueda N. Cloning and expression of a novel MAPKK-like protein kinase, specifically expressed in the testis and activated lymphoid cells. J Biol Chem. 2000;275:21525–21531
  3. Simons-Evelyn M, Bailey-Dell K, Toretsky JA, Ross DD, Fenton R, Kalvakolanu D, et al. PBK/TOPK is a novel mitotic kinase which is upregulated in Burkitt's lymphoma and other highly proliferative malignant cells. Blood Cells Mol Dis. 2001;27:825–829
  4. Yuryev A, Wennogle LP. Novel protein–protein interactions found by an exhaustive yeast two-hybrid analysis. Genomics. 2003;81:112–125
  5. Cote S, Simard C, Lemieux R. Regulation of growth-related genes by interleukin-6 in murine myeloma cells. Cytokine. 2002;20:113–120
  6. Nandi A, Tidwell M, Karp J, Rapoport AP. Protein expression of PDZ-binding kinase is strongly down-regulated during terminal differentiation of HL-60 leukemic cells. Blood Cells Mol Dis. 2004;32:240–245
  7. Garrington TP, Johnson GL. Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol. 1999;11:211–218
  8. Ono K, Han J. The p38 cell signal transduction pathway: activation and function. Cell Signal. 2000;12:1–13
  9. Matsumoto S, Abe Y, Fujibuchi T, Takeuchi T, Kito K, Ueda N, et al. Characterization of a MAPKK-like protein kinase TOPK. Biochem Biophys Res Commun. 2004;325:997–1004
  10. Terada Y. Role of chromosomal passenger complex in chromosome segregation and cytokinesis. Cell Struct Funct. 2001;26:653–657
  11. Spankuch-Schmitt B, Wolf G, Solbach C, Loibl S, Knecht R, Stegmuller M, et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene. 2002;21:3162–3171
  12. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol. 2001;2:21–32
  13. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA. 1985;82:790–794
  14. Wang X, Studzinski GP. Inhibition of p38 MAP kinase potentiates the JNK/SAPK pathway and AP-1 activity in monocytic but not in macrophage or granulocytic differentiation of HL60 cells. J Cell Biochem. 2001;82:68–77
  15. Nurse P. Checkpoint pathways comes of age. Cell. 1997;91:865–867
  16. Laiho M, Latonen L. Cell cycle control, DNA damage checkpoints and cancer. Annals Med. 2003;35:391–397
  17. Kahlem P, Dorken B, Schmitt CA. Cellular senescence in cancer treatment: friend or foe. J Clin Invest. 2004;113:169–174
  18. Agapova LS, Volodina JL, Chumakov PM, Kopnin BP. Activation of Ras-Ral pathway attenuates p53-independent DNA damage G2 checkpoint. J Biol Chem. 2004;279:36382–36389
  19. Erenpreisa J, Cragg MS. Mitotic death: a mechanism of survival? A review. Cancer Cell Int. 2001;1(1):1–7
  20. Eymin B, Leduc C, Coll JL, Brambilla E, Gazzeri S. p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene. 2003;22:1822–1835
  21. Normand G, Hemmati PG, Verdoodt B, von Haefen C, Wendt J, Guner D, et al. p14ARF induces G2 cell cycle arrest in p53 and p21 deficient cells by downregulating p34cdc2 kinase activity. J Biol Chem. 2005;280:7118–7130
  22. Polager S, Ginsberg D. E2F mediates sustained G2 arrest and downregulation of Stathmin and AIM-1 expression in response to genotoxic stress. J Biol Chem. 2003;278:1443–1449
  23. Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA, et al. E2F integrates cell cycle progression with DNA repair, replication, and (G2)/M checkpoints. Genes Dev. 2002;16:245–256
  24. Blais A, Dynlacht BD. Hitting their targets: an emerging picture of E2F and cell cycle control. Curr Opin Genet Dev. 2004;14:527–532
  25. Shi Y, Venkatraman SL, Dodson GE, Mabb AM, LeBlanc S, Tibbetts RS. Direct regulation of CREB transcriptional activity by ATM in response to genotoxic stress. Proc Natl Acad Sci USA. 2004;101:5898–5903
  26. Ono Y, Kawauchi J, Kitajima S, Marumo F, Isobe M. ATF3 inhibits doxorubicin-induced apoptosis in cardiac myocytes: a novel cardioprotective role of ATF3. J Mol Cell Cadiol. 2002;34:1387–1397
  27. Persengiev SP, Green MR. The role of ATF/CREB family members in cell growth, survival and apoptosis. Apoptosis. 2003;8:225–228
  28. Wang Y, Blandino G, Givol D. Induced p21Waf expression in H1299 cell line promotes cell senescence and protects against cytotoxic effect of radiation and doxorubicin. Oncogene. 1999;18:2643–2649
  29. Chang B-D, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, et al. A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. Cancer Res. 1999;59:3761–3767
  30. Chang B-D, Xuan Y, Broude EV, Zhu H, Schott B, Fang J, et al. Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene. 1999;18:4808–4818
  31. Sambrook J, Fritsch, EF, Maniatis, T, editors. Molecular cloning: a laboratory manual. 2nd ed., vol. 3, Cold Spring Harbor Laboratory Press; 1989.
  32. Sanchez Y, Wong C, Thoma RS, Richman R, Wu Z, Piwnica-Worms H, et al. Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. Science. 1997;277:1497–1501
  33. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature. 2003;421:499–506
  34. Kraft C. Mitotic entry: tipping the balance. Curr Biol. 2003;13:R445–R446
  35. Hoffman B, Amanullah A, Shafarenko M, Liebermann DA. The proto-oncogene c-Myc in hematopoietic development and leukemogenesis. Oncogene. 2002;21:3414–3421
  36. Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell. 2002;13:1977–2000
  37. Gilfillan S, Stelzer G, Piaia E, Hofmann MG, Meisterernst M. Efficient binding of NC2.TATA-binding protein to DNA in the absence of TATA. J Biol Chem. 2005;280:6222–6230
  38. Chittenden T, Livingston DM, DeCaprio JA. Cell cycle analysis of E2F in primary human T cells reveals novel E2F complexes and biochemically distinct forms of free E2F. Mol Cell Biol. 1993;13:3975–3983
  39. Zhu W, Giangrande PH, Nevins JR. E2Fs link the control of G1/S and G2/M transcription. EMBO J. 2004;23:4615–4626
  40. Giangrande PH, Zhu W, Schlisio S, Sun X, Mori S, Gaubatz S, et al. A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription. Genes Dev. 2004;18:2941–2951
  41. Wong K-K, Zou X, Merrell KT, Patel AJ, Marcu KB, Chellappan S, et al. v-Abl activates c-myc transcription through the E2F site. Mol Cell Biol. 1995;15:6535–6544
  42. Agulnick AD, Thompson JR, Ricciardi RP. An ATF/CREB site is the major regulatory element in the human herpesvirus 6 DNA polymerase promoter. J Virol. 1994;68:29970–29977
  43. Erdmann J. Cancer's big sleep: senescence may be potential target for cancer therapies. J Natl Cancer Inst. 2005;97:89–91
  44. Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hofmann RM, et al. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell. 2002;109:335–346
  45. Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer. 2002;2:331–341
  46. Murray AW. Recycling the cell cycle: cyclins revisited. Cell. 2004;116:221–234
  47. Seoane J, Le H-V, Massague J. Myc suppression of the p21(Cip1)Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 2002;419:729–734
  48. Passalaris TM, Benanti JA, Gewin L, Kiyono T, Galloway DA. The G(2) checkpoint is maintained by redundant pathways. Mol Cell Biol. 1999;19:5872–5881
  49. Elkon R, Linhart C, Sharan R, Shamir R, Shiloh Y. Genome-wide in silico identification of transcriptional regulators controlling the cell cycle in human cells. Genome Res. 2003;13:773–780
  50. Polzin RG, Benlhabib H, Trepel J, Herrera JE. E2F sites in the Op18 promoter are required for high level of expression in the human prostate carcinoma cell line PC-3-M. Gene. 2004;341:209–218

PII: S0145-2126(05)00320-6

doi: 10.1016/j.leukres.2005.08.011

Leukemia Research
Volume 30, Issue 4 , Pages 437-447 , April 2006

Article Tools

* Image Usage & Resolution